20th Annual Highlights of the 2021 San Antonio Breast Cancer Symposium

20th Annual Highlights of the 2021 San Antonio Breast Cancer Symposium

Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, this virtual CME is designed to help medical, radiation and surgical oncologists, gynecologists, radiologists, and primary care physicians translate the data from key presentations from the 2021 San Antonio Breast Cancer Symposium into practice.

Join speakers from Fox Chase and Penn Medicine’s Abramson Cancer Center as they present information on the treatment of breast cancer, including screening, prevention, local control, chemotherapy, hormonal therapy, and advances in breast cancer biologics and their impact on breast cancer management.

VIRTUAL CME: Thursday, January 20, 2022

5:30–9:30 pm Exhibit Hall Open
6:30–9:00 pm Education Program
9:00–9:30 pm Virtual Reception & Exhibit Hall

PROGRAM DIRECTOR

Lori J. Goldstein, MD, FASCO
Professor Emerita, Department of Hematology/Oncology,
Fox Chase Cancer Center

FACULTY

FOX CHASE CANCER CENTER

Richard J. Bleicher, MD, FACS
Professor, Department of Surgical Oncology; Leader, Breast Cancer Program; Director, Breast Fellowship Program

Lori J. Goldstein, MD, FASCO
Professor Emerita, Department of Hematology/Oncology,
Fox Chase Cancer Center

Elias Obeid, MD, MPH

Interim Chief, Division of Breast Medical Oncology; Assistant Professor, Department of Clinical Genetics and Department of Hematology/Oncology; Director, Breast, Ovarian and Prostate Cancer Risk Assessment

Kristen D. Whitaker, MD, MS

Assistant Professor, Department of Clinical Genetics and Department of Hematology/Oncology

PENN MEDICINE’S ABRAMSON CANCER CENTER

Susan M. Domchek, MD
Executive Director, Basser Center for BRCA; Director, MacDonald Cancer Risk Evaluation Center; Basser Professor in Oncology

Angela DeMichele, MD, MSCE

Jill & Alan Miller Endowed Chair in Breast Cancer Excellence
Professor of Medicine
Co-Leader, Breast Cancer Program
Co-Director, 2-PREVENT Translational Center of Excellence

LEARNING OBJECTIVES

After attending this program, participants should be able to:

  • Analyze the advances in the management of breast cancer and premalignant breast disease and, when clinically relevant, integrate new findings into the management of patients with breast cancer and premalignant breast disease.
  • When clinically relevant, apply new strategies for optimizing existing treatments into the management of these patients.
  • Analyze new developments in breast cancer research and current available clinical trials and, when clinically relevant, include this information in discussions with patients.

INTENDED AUDIENCE

The program is designed for medical, radiation and surgical oncologists, gynecologists, radiologists, and primary care physicians. Other physician specialties, nurses, advanced practice clinicians and healthcare professionals involved in the treatment of patients with breast cancer may find the program beneficial.

ACCREDITATION STATEMENT

The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity.

DISCLOSURE POLICY

It is the policy of the Temple Health Office for Continuing Medical Education to ensure that all sponsored continuing medical education activities are independently designed and produced and include content that is valid, objective, balanced, free of commercial bias and in the best interest to the public. Temple Health policy requires everyone in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest pertaining to the content of the activity and to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Temple Health Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity.


Published

October 20, 2021

Expires

January 20, 2023

Related Presenters

Lori J. Goldstein, MD, FASCO

Lori J. Goldstein, MD, FASCO

Professor Emerita, Department of Hematology/Oncology, Fox Chase Cancer Center

Richard J. Bleicher, MD, FACS

Richard J. Bleicher, MD, FACS

Professor, Department of Surgical Oncology; Leader, Breast Cancer Program; Director, Breast Fellowship Program

Elias Obeid, MD, MPH

Elias Obeid, MD, MPH

Interim Chief, Division of Breast Medical Oncology; Assistant Professor, Department of Clinical Genetics and Department of Hematology/Oncology; Director, Breast, Ovarian and Prostate Cancer Risk Assessment

Kristen D. Whitaker, MD, MS

Kristen D. Whitaker, MD, MS

Assistant Professor, Department of Clinical Genetics and Department of Hematology/Oncology